Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-683-1880
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees13
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable
Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics Inc (NASDAQ:AGRX) issued its quarterly earnings data on Tuesday, March, 12th. The specialty pharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.04. View Agile Therapeutics' Earnings History.
When is Agile Therapeutics' next earnings date?
What price target have analysts set for AGRX?
3 equities research analysts have issued 1-year price targets for Agile Therapeutics' shares. Their predictions range from $3.00 to $4.00. On average, they anticipate Agile Therapeutics' share price to reach $3.3333 in the next year. This suggests a possible upside of 108.6% from the stock's current price. View Analyst Price Targets for Agile Therapeutics.
What is the consensus analysts' recommendation for Agile Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics.
What are Wall Street analysts saying about Agile Therapeutics stock?
Here are some recent quotes from research analysts about Agile Therapeutics stock:
- 1. Maxim Group analysts commented, "Agile Therapeutics announced topline results from its comparative adhesion wear study of Twirla vs. Xulane (generic Otho-Evra). Twirla met its primary endpoint of non-inferiority to Xulane, which the FDA considers to have acceptable adhesion for a patch contraceptive. These results will be used to answer FDA adhesion questions from the 2017 CRL and will be included in the NDA package." (2/11/2019)
- 2. HC Wainwright analysts commented, "We don’t think this should even be required, as Twirla is a different product than Xulane/Ortho Evra, not a generic copy, so its benefit-risk profile—which we think is better—should stand on its own merits. Nevertheless, the minutes were consistent with our expectation for a straightforward two-week crossover study (one week on each patch) to show that Twirla adhesion is non-inferior (NI) to Xulane. The company has not disclosed the specific NI margin that the agency is requiring, but the planned sample size of only n=80 suggests to us that the FDA has given them some NI breathing room. We are confident in success based on Phase 3 adhesion data (more below). Agile already had the study teed up and ready to go, and has immediately initiated it with a dermatology-specialized CRO, TKL Research." (1/11/2019)
Has Agile Therapeutics been receiving favorable news coverage?
Media stories about AGRX stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Agile Therapeutics earned a coverage optimism score of 2.2 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Are investors shorting Agile Therapeutics?
Agile Therapeutics saw a decline in short interest in February. As of February 28th, there was short interest totalling 844,663 shares, a decline of 24.9% from the February 15th total of 1,125,414 shares. Based on an average daily trading volume, of 362,532 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.6% of the company's stock are sold short. View Agile Therapeutics' Current Options Chain.
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include Constellation Pharmaceuticals (CNST), Seres Therapeutics (MCRB), Protagonist Therapeutics (PTGX), Edge Therapeutics (EDGE), BIOFRONTERA AG/ADR (BFRA), Neptune Wellness Solutions (NEPT), TapImmune (MRKR), Xeris Pharmaceuticals (XERS), Calithera Biosciences (CALA), Dova Pharmaceuticals (DOVA), Verastem (VSTM), Tocagen (TOCA), AcelRx Pharmaceuticals (ACRX), Kamada (KMDA) and resTORbio (TORC).
What other stocks do shareholders of Agile Therapeutics own?
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Mr. Alfred F. Altomari, Chairman & CEO (Age 60)
- Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)
- Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)
- Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)
- Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62)
Who are Agile Therapeutics' major shareholders?
Agile Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (0.91%), Geode Capital Management LLC (0.67%), Geode Capital Management LLC (0.67%), BlackRock Inc. (0.39%) and Virtu Financial LLC (0.16%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Life Sciences Maste Perceptive and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.
Which major investors are selling Agile Therapeutics stock?
Which major investors are buying Agile Therapeutics stock?
AGRX stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Geode Capital Management LLC, Geode Capital Management LLC and BlackRock Inc.. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari and Renee Selman. View Insider Buying and Selling for Agile Therapeutics.
How do I buy shares of Agile Therapeutics?
Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of AGRX stock can currently be purchased for approximately $1.5980.
How big of a company is Agile Therapeutics?
Agile Therapeutics has a market capitalization of $69.05 million. The specialty pharmaceutical company earns $-19,780,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Agile Therapeutics employs 13 workers across the globe.
What is Agile Therapeutics' official website?
How can I contact Agile Therapeutics?
Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]
MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
